loncastuximab
adc therapeutics
['cml', 'lotis-2', 'adctherap']
updated results from our pivotal lotis-2 trial evaluating our cd19-targeted #antibodydrugconjugate will be presented in a poster today at #eha2023 and we look forward to the encore oral presentation at #17icml on june 15. learn more: 
Leading the development & commercialization of next-generation antibody drug conjugates with highly potent and targeted pyrrolobenzodiazepine dimer technology